1. Home
  2. Analysis
  3. Gemzar
  4. Status-epilepticus

Gemzar and Status epilepticus - a phase IV clinical study of FDA data

Summary:

Status epilepticus is reported as a side effect among people who take Gemzar (gemcitabine hydrochloride), especially for people who are male, 40-49 old, have been taking the drug for < 1 month also take Amitriptyline Hydrochloride, and have Metastatic carcinoma.

The phase IV clinical study analyzes which people have Status epilepticus when taking Gemzar. It is created by eHealthMe based on reports of 20,184 people who have side effects when taking Gemzar from the FDA, and is updated regularly.

What is Gemzar?

Gemzar has active ingredients of gemcitabine hydrochloride. It is often used in pancreatic carcinoma. eHealthMe is studying from 20,315 Gemzar users. Check the latest studies of Gemzar.

What is Status epilepticus?

Status epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure) is found to be associated with 672 drugs and 948 conditions by eHealthMe. Check the latest studies of Status epilepticus.

On Jul, 05, 2026

20,184 people reported to have side effects when taking Gemzar.
Among them, 11 people (0.05%) have Status epilepticus.

Could Gemzar cause Status epilepticus?

Among these 11 people:

How long have people been on Gemzar when they have Status epilepticus? *

  • < 1 month: 77.78 %
  • 1 - 6 months: 22.22 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Status epilepticus when taking Gemzar? *

  • female: 27.27 %
  • male: 72.73 %

What is the age of people who have Status epilepticus when taking Gemzar? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 72.73 %
  • 50-59: 0.0 %
  • 60+: 27.27 %

What are other drugs people take besides Gemzar? *

  1. Cisplatin: 2 people, 18.18%
  2. Amitriptyline Hydrochloride: 2 people, 18.18%

What are other side effects people have besides Status epilepticus? *

  1. Consciousness - Decreased: 2 people, 18.18%
  2. Csf Protein Increased: 2 people, 18.18%
  3. Headache (pain in head): 2 people, 18.18%
  4. Encephalopathy (functioning of the brain is affected by some agent or condition): 2 people, 18.18%
  5. Thrombocytopenia (decrease of platelets in blood): 1 person, 9.09%
  6. Fatigue (feeling of tiredness): 1 person, 9.09%
  7. Cerebral Ischaemia (insufficient blood flow to the brain to meet metabolic demand): 1 person, 9.09%
  8. Cerebral Ventricle Dilatation (enlargement of ventricle of brain): 1 person, 9.09%
  9. Confusional State: 1 person, 9.09%
  10. Fall: 1 person, 9.09%

What are the existing conditions these people have? *

  1. Metastatic Neoplasm (spreadable cancer tumour): 1 person, 9.09%
  2. Metastatic Carcinoma (cancer tumour spreads to other part of body): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Gemzar and have Status epilepticus?

- Check whether Status epilepticus is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gemzar:

Status epilepticus treatments and more:

How severe was Status epilepticus and when was it recovered:

Expand to all the drugs that have ingredients of gemcitabine hydrochloride:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Gemzar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Status epilepticus:

Browse all the conditions that are associated with Status epilepticus:

How the study uses the data?

The study uses data from the FDA. It is based on gemcitabine hydrochloride (the active ingredients of Gemzar) and Gemzar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.